(±)-Thalidomide-d4

(±)-Thalidomide-d4 is intended for use as an internal standard for the quantification of (±)-thalidomide (Cay-14610) by GC- or LC-MS. (±)-Thalidomide is an immunomodulatory compound with diverse biological activities, including anticancer, anti-inflammatory, and teratogenic properties. It prevents polymorphonuclear leukocyte (PMN) chemotaxis when used at concentrations of 1, 10, and 100 µg/ml. (±)-Thalidomide increases IL-2-induced proliferation and IFN-gamma production in primary human T cells in vitro. It enhances natural killer (NK) cell-mediated cytotoxicity in MM.1S multiple myeloma cells. Thalidomide (4 mg/animal) reduces lung IL-6, TGF-beta, VEGF, angiopoietin-1, angiopoietin-2, and collagen type Ialpha1 expression, inhibits pulmonary angiogenesis, and attenuates fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis. It induces apoptosis in primary human embryonic fibroblasts (EC50 = 8.9 µM) and induces limb and eye defects in chicken embryos (EC50 = 50 µg/kg egg weight). Formulations containing thalidomide have been used in the treatment of multiple myeloma and erythema nodosum leprosum (ENL) in non-pregnant individuals.Formal Name: 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione-4,5,6,7-d4. CAS Number: 1219177-18-0. Synonyms: N-Phthaloylglutamimide-d4. Molecular Formula: C13H6D4N2O4. Formula Weight: 262.3. Purity: >99% deuterated forms (d1-d4). Formulation: (Request formulation change), A solid. Solubility: DMF: 12 mg/ml, DMSO: 12 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.11 mg/ml. SMILES: O=C(C1=C2C([2H])=C([2H])C([2H])=C1[2H])N(C3C(NC(CC3)=O)=O)C2=O. InChi Code: InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/i1D,2D,3D,4D. InChi Key: UEJJHQNACJXSKW-RHQRLBAQSA-N.